MEDX ETF holdings (NASDAQ) - Page 2 | MetaTrader

Apri il grafico completo Full chart

Panoramica Tutti gli asset Mappa di calore

Principali partecipazioni Market Value Shares Weight %

Sandoz Group AG 137.6320 K 1 760.0000 0.7581%

GALT Galectin Therapeutics Inc 137.3405 K 49.2260 K 0.7565%

HLN Haleon PLC 129.1290 K 12.9000 K 0.7113%

REPL Replimune Group Inc 100.8882 K 13.1880 K 0.5557%

EDIT Editas Medicine Inc 71.6547 K 29.0100 K 0.3947%

GEHC GE HealthCare Technologies Inc 62.6384 K 880.0000 0.3450%

BCYC Bicycle Therapeutics PLC 61.1923 K 13.1880 K 0.3371%

VTRS Viatris Inc 44.2047 K 3 272.0000 0.2435%

ALLO Allogene Therapeutics Inc 42.9001 K 17.5820 K 0.2363%

LTRN Lantern Pharma Inc 36.1310 K 26.3730 K 0.1990%

PACB Pacific Biosciences of Califor 13.9273 K 10.5510 K 0.0767%

DCOY Decoy Therapeutics Inc 135.5000 20.7500 0.0007%

Pathos AI Inc 23.9920 K

1
2

Notizie

Medmix: ricavi 2025 in calo, dividendo tagliato dell’80%; azioni giù del 17%

Medmix FY25 revenue falls, dividend cut 80%; shares down 17%

Medmix FY 2025: i margini balzano di 90 punti base mentre i ricavi calano del 7,4%

Medmix FY 2025 slides: margins surge 90bps as revenue falls 7.4%

Earnings call transcript: Medmix sees margin growth amid revenue dip in H2 2025

Medical ETF (MEDX) Touches New 52-Week High

Stifel avvia copertura su Medmix con rating Buy e target di CHF14,50

Stifel initiates coverage on Medmix stock with Buy rating, CHF14.50 target

Eli Lilly Hits $1 Trillion Milestone: ETFs to Invest in

Horizon Kinetics Q3 2025 Commentary (HKHC)

ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data